title: [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy].
abstract: BACKGROUND
  Currently CA 125 is a marker of choice for monitoring ovarian cancer Nonetheless, scientists are still searching for new markers, which could provide additional information for the evaluation of treatment, especially in patients with normal CA 125 levels, despite the progression of the disease. According to the latest reports, OPN can be a potential new marker:
  
  
  OBJECTIVE
  Estimation of usefulness of OPN determinations in the monitoring of ovarian cancer patients.
  
  
  METHODS
  The study included 54 ovarian cancer patients, undergoing chemotherapy Markers were measured before, during and after treatment. The dynamics of the change of OPN levels was shown on line graphs, using Microsoft Excel programme. Statistical analysis was performed by Kaplan-Meier method and log-rank test.
  
  
  RESULTS
  44% of patients from the study group were found to have low CA 125 levels. In these cases only the increase of OPN concentration indicated recurrence of the disease. In 43% of patients the high initial CA 125 and OPN levels decreased during chemotherapy and complete regression was stated in these patients. Nevertheless, in 13/17 patients a repeated increase of OPN concentration signalling the recurrence, earlier than CA 125 and clinical recurrence manifestation, was observed. In 13% of patients high initial levels of markers did not decrease during chemotherapy which correlated with the progression of the disease. Our study showed that only the CA 125 levels had a significant influence (p=0.00063) on the disease-free survival time.
  
  
  CONCLUSIONS
  Our data suggest a potential usefulness of the OPN determinations in estimating ovarian cancer recurrence. Nonetheless, there was no correlation between the initial OPN concentration and the disease-free survival time.
authors.affiliation: Zakład Analityki i Biochemii Klinicznej, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach Polska, 44-101 Gliwice, ul. Wybrzeza Armii Krajowej 15. jmrochem@io.gliwice.pl
authors.forename: Jolanta
authors.initials: J
authors.lastname: Mrochem-Kwarciak
authors.forename: Izolda
authors.initials: I
authors.lastname: Mrochen-Domin
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wojcieszek
authors.forename: Regina
authors.initials: R
authors.lastname: Deja
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Chmura
authors.forename: Barbara
authors.initials: B
authors.lastname: Masłyk
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Nowara
authors.forename: Beata
authors.initials: B
authors.lastname: Kaleta
authors.forename: Zofia
authors.initials: Z
authors.lastname: Kołosza
authors.forename: Wiesława
authors.initials: W
authors.lastname: Bartnik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy*; D012372:ROC Curve; D012016:Reference Values; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C506895:SPP1 protein, human; D053495:Osteopontin